SEARCH

SEARCH BY CITATION

References

  • 1
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl. 5):S147S334.
  • 2
    Holgate ST, Canonica GW, Simons FER, Taglialatela M, Tharp M, Timmerman H et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33:13051324.
  • 3
    Howarth PH, Holmberg K. Allergic rhinitis an increasing clinical problem. Allergy 1995;50:45.
  • 4
    Weiss ST. Eat dirt – the hygiene hypothesis and allergic diseases. New Engl J Med 2002;347:930931.
  • 5
    AAAAI, The Allergy Report. Available at: http://www.theallergyreport.com (accessed January 2008).
  • 6
    Meltzer EO. Does rhinitis compromise night-time sleep and daytime productivity? Clin Exp All Rev 2002;2:6772.
  • 7
    Potter PC. Effectiveness and safety of new-generation antihistamines in allergenic rhinitis and urticaria. SA Fam Pract 2005;47:2428.
  • 8
    Bousquet J, Van Cauwenberge P, Bachert C, Canonica GW, Demoly P, Durham R et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003;58:192197.
  • 9
    Bousquet J, Van Cauwenberge P, Khaled NA, Bachert C, Baena-Cagnani CE, Bouchard J et al. Pharmacologic and anti-IgE treatment of allergic rhinitis (ARIA) update (in collaboration with GA2LEN). Allergy 2006;61:10861096.
  • 10
    Van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55:116134.
  • 11
    Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CEH, Greaves MW, Henz BM et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321331.
  • 12
    Monroe E. Review of Hi antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005;76:118126.
  • 13
    Gregory C, Cifaldi M, Tanner LA. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care 1999;5:485496.
  • 14
    Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic asthma in Europe. Eur Respir J 2004;24:758764.
  • 15
    Nathan RA, Meltzer EO, Selner JC, Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99(6 Suppl. 2):S808S814.
  • 16
    Foley S, Hamid Q. Inflammatory patterns in allergic rhinitis. Clin Exp Allergy Rev 2006;6:9195.
  • 17
    Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108(Suppl. B):S2S8.
  • 18
    Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997;99(Suppl.):S773S780.
  • 19
    Grossmann J. One airway, one disease. Chest 1997;111(Suppl. 2):11S16S.
  • 20
    O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197201.
  • 21
    Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003;3:363368.
  • 22
    Grattan CEH. Towards rationalizing the nomenclature and classification of urticaria: some guidance on guidelines. Clin Exp Allergy 2007;37:625626.
  • 23
    Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CEH, Greaves MW, Henz BM et al. EAACI/GA2LEN guideline definition, classification and diagnosis of urticaria. Allergy 2006;61:316320.
  • 24
    Negro-Alvarez JM, Miraller-López JC. Chronic idiopathic urticaria treatment. Allergol Immunopathol 2001;29:129132.
  • 25
    Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004;64:25152536.
  • 26
    Garcia-Rafanell J. Rupatadine fumarate: antiallergic, histamine and PAF antagonist. Drugs Fut 1996;21:10331036.
  • 27
    Van Den Anker-Rakhmanina NY. Rupatadine. Curr Opin Anti-inflamm Immumomodul Invest Drugs 2000;2:127132.
  • 28
    Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine, a new selective histamine HI receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003;39:451468.
  • 29
    Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006;7:19892001.
  • 30
    Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007;67:457474.
  • 31
    Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000;55:716.
  • 32
    Quraishi SA, Davies MJ, Craig TJ. Inflammatory responses in allergic rhinitis: traditional approaches and novel treatment strategies. J Am Osteopathol Assoc 2004;104(Suppl. 5):S7S15.
  • 33
    Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol 1999;104:S132S137.
  • 34
    Bascom R, Pipkorn U, Proud D, Dunette S, Gleich GJ, Lichtenstein LM et al. Major basic protein and eosinophils-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989;84:338346.
  • 35
    Bascom R, Pipkorn U, Lichtenstein LM, Naclerio RM. The influx of inflammatory cells into nasal washings during the late-phase response to antigen challenge. Effect of systemic steroid pretreatment. Am Rev Respir Dis 1988;138:406412.
  • 36
    Horak F. Clinical advantages of dual activity in allergic rhinitis. Allergy 2000;55(Suppl. 64):3439.
  • 37
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997;280:114121.
  • 38
    Barrón S, Ramis I, Garcia-Rafanell J, Merlos M. Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity. Methods Find Exp Clin Pharmacol 2005;27(Suppl. 2):161162.
  • 39
    Giral M, Balsa D, Ferrando R, Merlos M, Garcia-Rafanell J, Forn J. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor (PAF) and histamine. Allergy 1998;53(Suppl.):131.
  • 40
    Merlos M, Balsa D, Giral M, Ferrando R, Garcia-Rafanell J, Forn J. Inhibition of rat peritoneal mast cell exocytosis by rupatadine fumarate: a study with different secretagogues. Methods Find Exp Clín Pharmacol 1997;19(Suppl. A):148.
  • 41
    Merlos M, Ferrando R, Giral M, Ramis I, Forn J. Effect of topical rupatadine in experimental conjunctivitis in guinea pigs: macroscopic evaluation of ocular lesions. J Allergy Clin lmmunol 2001;107(Suppl. 2):S310.
  • 42
    Queralt M, Merlos M, Giral M, Puigdemont A. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Dev Res 1996;39:1218.
  • 43
    Queralt M, Brazis P, Merlos M, Puigdemont A. lnhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev Res 1998;44:4955.
  • 44
    Queralt M, Brazís P, Merlos M, De Mora F, Puigdemont A. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-I. lnflamm Res 2000;49:355360.
  • 45
    Ferrando R, Giral M, Balsa D, Merlos M, Garcia-Rafanell J, Forn J. Protective effect of rupatadine fumarate in experimental conjunctivitis in guinea pigs. Methods Find Exp Clin Pharmacol 1996;18(Suppl. B):140.
  • 46
    Stuebner P, Horak F, Zieglmayer R, Arnáiz E, Leuratti C, Peréz I et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2006;96:3744.
  • 47
    Izquierdo I, Nieto C, Ramis J, Cooper M, Dewland P, Forn J. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers. Methods Find Exp Clin Pharmacol 1997;19(Suppl. A):189203.
  • 48
    Barbanoj MJ, García-Gea C, Morte A, Izquierdo I, Pérez I, Jané F. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004;50:311321.
  • 49
    Curtin ML. Current status of platelet-activating factor antagonists. Exp Opin Ther Patents 1998;8:703711.
  • 50
    Marques SA, Dy LC, Southall MD, Yi Q, Smietana E, Kapur R et al. The platelet-activating factor receptor activates the extracellular signal-regulated kinase mitogen-activated protein kinase and induces proliferation of epidermal cells through an epidermal growth factor-receptor-dependent pathway. J Pharmacol Exp Ther 2002;300:10261035.
  • 51
    Merlos M, Ramis I, Balsa D, Queralt M, Brazis P, Pugidemont A. Inhibitory effect of rupatadine on TNF-α release from human monocytes and mast cell line HMC-1. J Allergy Clin lmmunol 2000;105(Suppl. 1):S62.
  • 52
    Barrón S, Ramis I, Merlos M. Rupatadine inhibits the inflammatory component of allergic response: cytokine release, adhesion molecule expression and inflammatory cell recruitment. 23rd EAACI Congress, 12–16 June 2004, Amsterdam.
  • 53
    Merlos M, Giral M, Balsa D, Ferrando R, Garcia-Rafanell J, Forn J. Rupatadine inhibits the eosinophil recruitment in BAL fluid of ovalbumin-sensitized guinea pigs. J Allergy Clin lmmunol 1998;101(Suppl. 1):S218.
  • 54
    Ramis I, Giral M, Ferrando R, Merlos M. Inhibition of PAF- and LTB4-induced human neutrophil chemotaxis by rupatadine using a new fluorescent chemotaxis assay. Allergy 2000;55(Suppl. 63):9495.
  • 55
    Barrón S, Roman J, Michelena P, Ramis I, Merlos M. Rupatadine inhibits cytokine production and NF-κB activity by histamine H1 receptor-dependent mechanism. Rev Rinol 2006;6:18.
  • 56
    Barrón S, Ramis I, Merlos M. Effect of rupatadine on lymphocyte cytokine production. Allergy Clin Immunol Int 2005;1(Suppl. 1):427.
  • 57
    Scannell RT, Differding E, Talaga P. Dual acting antihistaminergic agents. Mini Rev Med Chem 2004;4:923933.
  • 58
    Roumestan C, Henriquet C, Mathieu M, Bousquet J. Effects of rupatadine on inflammatory mediators and transcription factors: a comparison with desloratadine and levocetirizine Allergy Clin Immunol Int 2005;(Suppl. 1):450.
  • 59
    Mion O, Mello Jr J, Castro F, Cruz A, Mocelin M, Bogart P et al. Rupatadine fumarate is effective in the treatment of persistent allergic rhinitis: a multicentre study. Allergy 2007;62(Suppl. 83):137.
  • 60
    Izquierdo I, Paredes I, Lurigados C, Sospedra E, Cooper M, Thomas H. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy 2000;55(Suppl. 63):275.
  • 61
    Pérez I, De la Cruz G, Villa M, Izquierdo I. Rupatadine in allergic rhinitis: pooled analysis of efficacy data. Allergy 2002;57(Suppl. 73):245.
  • 62
    Saint-Martin F, Dumur JP, Pérez I, Izquierdo I. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and HI receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J lnvestig Allergol Clin Immunol 2004;14:3440.
  • 63
    Martinez-Cócera C, De Molina M, Marti-Guadaño E, Pola J, Conde J, Borja J et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J lnvestig Allergol Clin Immunol 2005;15:2229.
  • 64
    Guadaño EM, Serra-Batlles J, Meseguer J, Castillo JA, De Molina M, Valero A et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004;59:766771.
  • 65
    Valero A, Bartra J, Serrano C, Donado E, Garcia O, Izquierdo I et al. Rupatadine reduces nasal obstruction in allergen-induced rhinitis. Allergy 2007;62(Suppl. 83):137138.
  • 66
    Roger A, Arnáiz E, Valero A, De la Torre F, Castillo JA, Rivas P et al. Rupatadine 10 mg improves quality of life in long-term treatment of persistent allergic rhinitis [abstract no. 761 plus poster]. 25th EAACI Congress 10–14 June 2006, Vienna.
  • 67
    Fantin S, Maspero J, Bisbal C, Agache I, Donado E, Garcia O et al. A 12-week placebo-controlled study of rupatadine 10 mg once daily comparative with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. In press, Allergy, 2008.
  • 68
    Gimenez-Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy 2007;62:539546.
  • 69
    Dubertret L, Zalupca L, Cristodoulo T, Benea V, Medina I, Fantin S et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007;17:223228.
  • 70
    Gimenez-Arnau A, Donado E, Arnaiz E, Perez I, Izquierdo I. Fast onset of action of rupatadine in the reduction of pruritus in patients suffering from chronic urticaria: pooled analysis. Allergy 2007;62(Suppl. 83):306.
  • 71
    Gimenez-Arnau A, Perez I, Donado E, Pujol-Vallverdú RM, Arnaiz E, Izquierdo I. The use of a responder analysis to identify clinical meaningful differences in patients suffering from chronic urticaria following a 4-weeks treatment with rupatadine 10-and 20 mg. World Congress of Dermatology, 1–5 October 2007, Buenos Aries.
  • 72
    Juniper EF. Can quality of life be quantified? Clin Exp All Rev 2002;2:5760.
  • 73
    Solans A, Merlos M, Antonijoan R, Barbanoj M, Donado E, Izquierdo I et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin: a randomized, crossover, multiple-dose open study. Allergy Clin Immunol Int 2005;(Suppl. 1):159.
  • 74
    Solans A, Carbó M, Peña J, Nadal T, Izquierdo I, Merlos M. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin Therap 2007;29:900908.
  • 75
    Barbanoj MJ, García-Gea C, Antonijoan R et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol Clin Exp 2006;21:1326.
  • 76
    Efficacy Guideline. El: The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. ICH Harmonised Tripartate Guideline, 1995. Available at: http://www.ich.org (accessed January 2008).
  • 77
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis. Available at: http://www.emea.europa.eu (accessed January 2008).
  • 78
    Valero A, Rivas P, Castillo JA, Borja J, Donado E, Arnaiz E et al. One year safety data of rupatadine 10 mg in patients with allergic rhinitis. 25th EAACI Congress 10–14 June, 2006, Vienna.
  • 79
    Gimenez-Arnau A, Pujol R, Donado E, Arnaiz E, Perez I, Izquierdo I. Safety profile of rupatadine in the treatment of chronic urticaria. Allergy 2007;62(Suppl. 83):306.
  • 80
    Hove-Madsen L, Llach A, Molina CE, Prat-Vidal C, Farré J, Roura S et al. The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. Eur J Pharmacol 2006;553:215221.
  • 81
    Dávila I, Sastre J, Bartra J, Del Cuvillo A, Jáuregui I, Montoro J et al. Effect of H1 antihistamines upon the cardiovascular system. J Invest Allergol Clin Immunol 2006;16(Suppl. 1):1323.
  • 82
    Donado E, García O, Pérez I, Barbanoj M, Antonijoan R, Péna J et al. Cardiac safety of rupatadine according to the new ICH guideline: a “thorough QT/QTc study” [abstract no. 760 plus poster]. 25th EAACI Congress 10–14 June, 2006, Vienna.
  • 83
    Izquierdo I, Pérez I, Villa M, Giral M, Merlos M, Forn J. Lack of electrocardiographic effects of rupatadine, new nonsedating selective histamine H1-receptor and PAF antagonist. Allergy 2001;56(Suppl. 68):212.
  • 84
    Giral M, Merlos M, Balsa D, Ferrando R, Garcia-Rafanell J, Forn J. Effects of rupatadine on cardiovascular profile in rats and guinea pigs: comparison with other nonsedating antihistamines. Allergy 1997;52(Suppl. 37):4445.
  • 85
    Ramis I, Giral M, Nieto C, Martel E, Merlos M. Lack of cardiotoxic effects of rupatadine in isolated Purkinje fibres and its relationship with rupatadine cardiac levels. Allergy 2000;55(Suppl. 63):264.
  • 86
    Caballero R, Valenzuela C, Longobardo M, Tamargo J, Delpón E. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br J Pharmacol 1999;128:10711081.
  • 87
    Antonijoan R, Garcia-Gea C, Ballester M, Donado E, Perez I, Blanch I et al. Rupatadine not potentiate the depressant CNS effects of benzodiazepines. Allergy 2007;62(Suppl. 83):490.
  • 88
    Vuurman E, Theunissen E, Van Oers A, Van Leeuwen C, Jolles J. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Human Psychopharmacol Clin Exp 2007;22:289297.
  • 89
    Bousquet J. Is the impairment of quality of life acceptable for the patient? Clin Exp All Rev 2002;2:6165.
  • 90
    Bachert C. Quality of life: improvement due to treatment. Clin Exp All Rev 2002;2:7378.
  • 91
    Finlay AY, Khan GK. Dermatology Life Quality lndex (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;9:210216.
  • 92
    Tillement J-P. Pharmacological profile of the new antihistamines. Clin Exp All Rev 2005;5:711.
  • 93
    Walsh GM. Anti-inflammatory properties of antihistamines: an update. Clin Exp All Rev 2005;5:2125.
  • 94
    Devillier P. Comparing the new antihistamines: the role of pharmacological parameters. Clin Exp Allergy 2006;36:57.